Compare Amgen, Inc. (AMGN) vs CleanSpark Inc (CLSK) Price & Performance

Amgen (AMGN) trades at $416.74, showing minimal daily movement with a slight 0.11% decline. The stock maintains strong technical momentum with bullish moving averages and support at $412. Fundamentally, the company demonstrates robust performance with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, while revenue growth continues with 2025 revenue reaching $36.75 billion. Analyst sentiment remains positive with 59% buy ratings, though the current price exceeds the consensus target of $394.69.

Amgen presents a mixed outlook with strong earnings momentum and product growth offset by valuation concerns. Investment opportunities include continued blockbuster drug performance and raised 2026 guidance, while risks involve high debt levels and potential data breach litigation impacts. The stock's current premium valuation requires sustained execution to justify further upside.

CleanSpark (CLSK) trades at $12.23, up 5.52% today but showing bearish technical signals with recent earnings misses. The company reported a Q3 2026 loss of $0.89 per share versus expectations of $0.47, continuing a trend of negative profitability despite securing a significant $6.6 billion AI data center lease. Revenue declined to $679 million in 2026 with a negative profit margin of -146.91%, though analyst consensus remains unanimously bullish with a $24.13 price target.

The stock presents a high-risk opportunity with strong institutional support but significant fundamental challenges. While the AI infrastructure pivot offers long-term potential, near-term execution risks and persistent losses require careful monitoring. The 100% buy rating from analysts suggests confidence in the strategic shift, but investors must weigh the substantial valuation premium against ongoing cash burn and competitive pressures.